Interesting form Ihub
docj
Re: None
Wednesday, April 02, 2025 6:29:45 PM
Post#
234912
of 234921
Tiny-Ad-8280
“It’s Just a Poster…” Until It Saves Lives. 40 Days...
Let’s not sugarcoat it.
“It’s just a poster.” “We’ve been here before.” “If this were real, we’d already know.”
That’s what they’re saying.
Some with cynicism.
Some with scars.
And honestly? I get it.
But if you’ve ever paid attention to oncology, you know:
The biggest revolutions start small.
And this one — if it holds — could be one of the biggest of all.
???? Let’s rewind to 2015
Immunomedics walked into ASCO with Trodelvy, a drug nobody cared about yet.
58 women with stage 4 triple-negative breast cancer
17 had some tumor shrinkage
2 had full tumor disappearance
No survival data
No media frenzy
Just a quiet little poster tacked to a wall
No one said,
“This changes everything.”
But five years later?
Trodelvy becomes the largest breast cancer acquisition in history.
$21 billion.
Because that poster was the spark.
It didn’t show a cure.
It showed a signal.
???? Now it’s 2025. And Leronlimab is bringing more than a signal.
It’s not just a tumor response.
It’s not a 3-month bump in survival.
It’s stage 4 breast cancer patients — alive and well, three years later.
It’s people who failed every line of chemo — now cancer-free.
It’s data that, if true, doesn’t just whisper “potential.”
It screams: hope is back.
Let me make this brutally clear:
✅ This is metastatic triple-negative breast cancer
✅ The kind that kills in 6–12 months, even with treatment
✅ These women were told, “There’s nothing more we can do.”
✅ And now some are alive 36+ months later, with no cancer left to find
You don’t see that.
Not in this disease.
Not at this stage.
Not ever.
???? Let’s stack it side by side — facts only:
???? Trodelvy (2015) vs Leronlimab (2025)
Poster vs Poster. Hope vs Survival.
Metric Trodelvy (2015 Poster at ASCO) Leronlimab (2025 Poster at ESMO)
Trial Phase Phase 1/2 Phase 1b/2 (Basket Trial)
Patients 58 with mTNBC (chemo-refractory) 30 with mTNBC (chemo-refractory)
Tumor Shrinkage 17 of 58 (~31% response rate) Some complete responses (NED); numbers coming at ESMO
Complete Remissions 2 confirmed Confirmed NED cases; final count revealed at ESMO
Median Survival Not reported >50% alive at 12 months
Long-Term Survivors None reported 36+ monthsSome alive , cancer-free
Grade 3/4 Side Effects 39% neutropenia, 13% diarrhea (chemo-like toxicity) Zero Grade 3/4 treatment-related adverse events
Now let me decode that last line for everyone without a medical degree:
???? Trodelvy’s early success came with real toxicity.
4 in 10 patients developed neutropenia — dangerously low white blood cells that can lead to life-threatening infections.
Over 1 in 10 had severe diarrhea — the kind that can land you in the hospital.
These are Grade 3 or 4 side effects, the most serious in cancer trials. They’re manageable — but not easy. This is classic, brutal chemo.
???? Leronlimab’s early trial?
Zero of those severe, drug-related side effects reported.
Not one patient experienced life-altering toxicity due to the drug.
No fevers. No bone marrow suppression. No emergency transfusions.
Just a targeted immune modulator that — somehow — gave patients time, without taking their quality of life.
You know what that means?
These women weren’t just alive longer.
They were living longer — without suffering.
That is not normal. That is not expected. That is not pharma-as-usual.
That is a breakthrough.
“But it’s just a poster…”
Yes.
So was Trodelvy.
So were the first data points from Keytruda, from Opdivo, from every life-saving drug in oncology history.
Because posters are where revolutions begin.
And this one?
Might be the most important ever tacked to a conference wall.
TL;DR:
“We’ve seen this before.”
No. You haven’t.
You’ve seen companies chase survival.
Now you’re seeing it.
You’ve seen drugs buy patients time.
Now you’re seeing people beat the clock.
And in 40 days, on a poster board in Munich,
you’ll see the data that proves it.
So roll your eyes.
Call it hype.
Say “we’ve heard this before.”
But when those survival curves drop…
when you see “36+ months” in a disease that gives you 6…
You’ll remember this post.
And you’ll realize:
This wasn’t another story.
This was the beginning of the ending — of metastatic breast cancer.
— Tiny ????
docj
Re: None
Wednesday, April 02, 2025 6:29:45 PM
Post#
234912
of 234921
Tiny-Ad-8280
“It’s Just a Poster…” Until It Saves Lives. 40 Days...
Let’s not sugarcoat it.
“It’s just a poster.” “We’ve been here before.” “If this were real, we’d already know.”
That’s what they’re saying.
Some with cynicism.
Some with scars.
And honestly? I get it.
But if you’ve ever paid attention to oncology, you know:
The biggest revolutions start small.
And this one — if it holds — could be one of the biggest of all.
???? Let’s rewind to 2015
Immunomedics walked into ASCO with Trodelvy, a drug nobody cared about yet.
58 women with stage 4 triple-negative breast cancer
17 had some tumor shrinkage
2 had full tumor disappearance
No survival data
No media frenzy
Just a quiet little poster tacked to a wall
No one said,
“This changes everything.”
But five years later?
Trodelvy becomes the largest breast cancer acquisition in history.
$21 billion.
Because that poster was the spark.
It didn’t show a cure.
It showed a signal.
???? Now it’s 2025. And Leronlimab is bringing more than a signal.
It’s not just a tumor response.
It’s not a 3-month bump in survival.
It’s stage 4 breast cancer patients — alive and well, three years later.
It’s people who failed every line of chemo — now cancer-free.
It’s data that, if true, doesn’t just whisper “potential.”
It screams: hope is back.
Let me make this brutally clear:
✅ This is metastatic triple-negative breast cancer
✅ The kind that kills in 6–12 months, even with treatment
✅ These women were told, “There’s nothing more we can do.”
✅ And now some are alive 36+ months later, with no cancer left to find
You don’t see that.
Not in this disease.
Not at this stage.
Not ever.
???? Let’s stack it side by side — facts only:
???? Trodelvy (2015) vs Leronlimab (2025)
Poster vs Poster. Hope vs Survival.
Metric Trodelvy (2015 Poster at ASCO) Leronlimab (2025 Poster at ESMO)
Trial Phase Phase 1/2 Phase 1b/2 (Basket Trial)
Patients 58 with mTNBC (chemo-refractory) 30 with mTNBC (chemo-refractory)
Tumor Shrinkage 17 of 58 (~31% response rate) Some complete responses (NED); numbers coming at ESMO
Complete Remissions 2 confirmed Confirmed NED cases; final count revealed at ESMO
Median Survival Not reported >50% alive at 12 months
Long-Term Survivors None reported 36+ monthsSome alive , cancer-free
Grade 3/4 Side Effects 39% neutropenia, 13% diarrhea (chemo-like toxicity) Zero Grade 3/4 treatment-related adverse events
Now let me decode that last line for everyone without a medical degree:
???? Trodelvy’s early success came with real toxicity.
4 in 10 patients developed neutropenia — dangerously low white blood cells that can lead to life-threatening infections.
Over 1 in 10 had severe diarrhea — the kind that can land you in the hospital.
These are Grade 3 or 4 side effects, the most serious in cancer trials. They’re manageable — but not easy. This is classic, brutal chemo.
???? Leronlimab’s early trial?
Zero of those severe, drug-related side effects reported.
Not one patient experienced life-altering toxicity due to the drug.
No fevers. No bone marrow suppression. No emergency transfusions.
Just a targeted immune modulator that — somehow — gave patients time, without taking their quality of life.
You know what that means?
These women weren’t just alive longer.
They were living longer — without suffering.
That is not normal. That is not expected. That is not pharma-as-usual.
That is a breakthrough.
“But it’s just a poster…”
Yes.
So was Trodelvy.
So were the first data points from Keytruda, from Opdivo, from every life-saving drug in oncology history.
Because posters are where revolutions begin.
And this one?
Might be the most important ever tacked to a conference wall.
TL;DR:
“We’ve seen this before.”
No. You haven’t.
You’ve seen companies chase survival.
Now you’re seeing it.
You’ve seen drugs buy patients time.
Now you’re seeing people beat the clock.
And in 40 days, on a poster board in Munich,
you’ll see the data that proves it.
So roll your eyes.
Call it hype.
Say “we’ve heard this before.”
But when those survival curves drop…
when you see “36+ months” in a disease that gives you 6…
You’ll remember this post.
And you’ll realize:
This wasn’t another story.
This was the beginning of the ending — of metastatic breast cancer.
— Tiny ????
12
